The U.S. Food and Drug Administration (FDA) has released an analysis of the "benefits outweighs the risks" of administering the Pfizer vaccine to children.
According to the Associated Press and Bloomberg, the FDA said in a report about giving children 5-11 years of age the Pfizer vaccine at one-third the adult dose.
The FDA analyzed that the benefit of preventing death or hospitalization due to COVID-19 outweighs the risk of side effects such as myocarditis in most scenarios given under these conditions.
Whether or not to approve the emergency use of Pfizer's vaccine for children aged 5-11 is expected to be finalized when an advisory body outside the FDA decides on the 26th.
When an approval recommendation is issued, the Centers for Disease Control and Prevention (CDC) will select children to be vaccinated and vaccinate as early as next month, the Associated Press predicted.
(Photo = Getty Images Korea)Keywords: